Botulinum Toxins, Type A

"Botulinum Toxins, Type A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25.

Descriptor ID	D019274
MeSH Number(s)	D08.811.277.656.300.480.153.100 D08.811.277.656.675.374.153.100 D12.776.097.156.100 D23.946.123.179.050
Concept/Terms	Botulinum Toxins, Type A Botulinum Toxins, Type A Botulinum Neurotoxin A Neurotoxin A, Botulinum Clostridium botulinum A Toxin Clostridium Botulinum Toxin Type A Botulinum A Toxin Toxin, Botulinum A Botulinum Toxin Type A Meditoxin Meditoxin Neuronox Oculinum Oculinum

Below are MeSH descriptors whose meaning is more general than "Botulinum Toxins, Type A".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Peptide Hydrolases [D08.811.277.656]
Endopeptidases [D08.811.277.656.300]
Metalloendopeptidases [D08.811.277.656.300.480]
Botulinum Toxins [D08.811.277.656.300.480.153]
Botulinum Toxins, Type A [D08.811.277.656.300.480.153.100]
Metalloproteases [D08.811.277.656.675]
Metalloendopeptidases [D08.811.277.656.675.374]
Botulinum Toxins [D08.811.277.656.675.374.153]
Botulinum Toxins, Type A [D08.811.277.656.675.374.153.100]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Bacterial Proteins [D12.776.097]
Botulinum Toxins [D12.776.097.156]
Botulinum Toxins, Type A [D12.776.097.156.100]
Biological Factors [D23]
Toxins, Biological [D23.946]
Bacterial Toxins [D23.946.123]
Botulinum Toxins [D23.946.123.179]
Botulinum Toxins, Type A [D23.946.123.179.050]

Below are MeSH descriptors whose meaning is related to "Botulinum Toxins, Type A".

Below are MeSH descriptors whose meaning is more specific than "Botulinum Toxins, Type A".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Botulinum Toxins, Type A" by people in this website by year, and whether "Botulinum Toxins, Type A" was a major or minor topic of these publications.

Bar chart showing 16 publications over 10 distinct years, with a maximum of 3 publications in 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	1	1	2
2009	1	0	1
2012	1	0	1
2013	2	0	2
2015	1	0	1
2016	1	0	1
2018	3	0	3
2020	2	0	2
2022	1	0	1
2023	2	0	2

Below are the most recent publications written about "Botulinum Toxins, Type A" by people in Profiles.

Shapiro K, Anger J, Cameron AP, Chung D, Daignault-Newton S, Ippolito GM, Lee U, Mourtzinos A, Padmanabhan P, Smith AL, Suskind AM, Tenggardjaja C, Van Til M, Brucker BM. Antibiotic use, best practice statement adherence, and UTI rate for intradetrusor onabotulinumtoxin-A injection for overactive bladder: A multi-institutional collaboration from the SUFU Research Network (SURN). Neurourol Urodyn. 2024 Feb; 43(2):407-414.

View in: PubMed
Barry KK, Reusch DB, Shahriari N, Lonowski S, Dedeoglu F, Vleugels RA. Botulinum toxin for refractory Raynaud's phenomenon: A "how to" guide for pediatric patients. Pediatr Dermatol. 2023 May-Jun; 40(3):587-589.

View in: PubMed
Reynolds WS, Suskind AM, Anger JT, Brucker BM, Cameron AP, Chung DE, Daignault-Newton S, Lane GI, Lucioni A, Mourtzinos AP, Padmanabhan P, Reyblat PX, Smith AL, Tenggardjaja CF, Lee UJ. Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: Multi-institutional collaboration from the SUFU research network. Neurourol Urodyn. 2022 02; 41(2):662-671.

View in: PubMed
Kopcsay KS, Marczak TD, Jeppson PC, Cameron AP, Khavari R, Tefera E, Gutman RE. Treatment of refractory overactive bladder with OnabotulinumtoxinA vs PTNS: TROOP trial. Int Urogynecol J. 2022 04; 33(4):851-860.

View in: PubMed
Yin L, Masuyer G, Zhang S, Zhang J, Miyashita SI, Burgin D, Lovelock L, Coker SF, Fu TM, Stenmark P, Dong M. Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy. PLoS Biol. 2020 03; 18(3):e3000618.

View in: PubMed
Chiu SY, Patel B, Burns MR, Legacy J, Wagle Shukla A, Ramirez-Zamora A, Deeb W, Malaty IA. High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy. Tremor Other Hyperkinet Mov (N Y). 2020; 10.

View in: PubMed
Weller JL, Comeau D, Otis JAD. Myofascial Pain. Semin Neurol. 2018 12; 38(6):640-643.

View in: PubMed
McAlindon TE, Schmidt U, Bugarin D, Abrams S, Geib T, DeGryse RE, Kim K, Schnitzer TJ. Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study. Osteoarthritis Cartilage. 2018 10; 26(10):1291-1299.

View in: PubMed
Filippakis A, Ho DT, Small JE, Small KM, Ensrud ER. Radiation-Induced Painful Neurogenic Hypertrophy Treated With Botulinum Toxin A. J Clin Neuromuscul Dis. 2018 Mar; 19(3):135-137.

View in: PubMed
Mahmoud BH, Ozog D, Burnett C, Cohen JL. Prospective Randomized Split-Face Comparative Study Between Topical Botulinum Toxin A Surface Application and Local Injection for Crow's Feet. Dermatol Surg. 2016 Apr; 42(4):554-6.

View in: PubMed

People

Explore

Similar Concepts

Top Journals